nodes	percent_of_prediction	percent_of_DWPC	metapath
Ruxolitinib—LTK—tongue—peripheral nervous system neoplasm	0.0088	0.0491	CbGeAlD
Ruxolitinib—Myelosuppression—Topotecan—peripheral nervous system neoplasm	0.00608	0.0196	CcSEcCtD
Ruxolitinib—Myelosuppression—Melphalan—peripheral nervous system neoplasm	0.00595	0.0192	CcSEcCtD
Ruxolitinib—BMPR2—ganglion—peripheral nervous system neoplasm	0.00591	0.033	CbGeAlD
Ruxolitinib—CAMK2G—nerve—peripheral nervous system neoplasm	0.00536	0.0299	CbGeAlD
Ruxolitinib—LRRK2—nerve—peripheral nervous system neoplasm	0.00531	0.0296	CbGeAlD
Ruxolitinib—CAMK2G—ganglion—peripheral nervous system neoplasm	0.00529	0.0295	CbGeAlD
Ruxolitinib—LRRK2—ganglion—peripheral nervous system neoplasm	0.00524	0.0292	CbGeAlD
Ruxolitinib—DCLK3—trigeminal ganglion—peripheral nervous system neoplasm	0.00514	0.0286	CbGeAlD
Ruxolitinib—Myelosuppression—Dactinomycin—peripheral nervous system neoplasm	0.00493	0.0159	CcSEcCtD
Ruxolitinib—ROCK1—Irinotecan—Topotecan—peripheral nervous system neoplasm	0.00483	0.344	CbGdCrCtD
Ruxolitinib—RPS6KA6—brainstem—peripheral nervous system neoplasm	0.0048	0.0267	CbGeAlD
Ruxolitinib—PLK3—trigeminal ganglion—peripheral nervous system neoplasm	0.00452	0.0252	CbGeAlD
Ruxolitinib—Myelosuppression—Vincristine—peripheral nervous system neoplasm	0.0044	0.0142	CcSEcCtD
Ruxolitinib—CAMK1—trigeminal ganglion—peripheral nervous system neoplasm	0.00423	0.0236	CbGeAlD
Ruxolitinib—Myelosuppression—Cisplatin—peripheral nervous system neoplasm	0.00389	0.0126	CcSEcCtD
Ruxolitinib—Myelosuppression—Etoposide—peripheral nervous system neoplasm	0.00357	0.0115	CcSEcCtD
Ruxolitinib—JAK1—trigeminal ganglion—peripheral nervous system neoplasm	0.00347	0.0194	CbGeAlD
Ruxolitinib—DCLK1—trigeminal ganglion—peripheral nervous system neoplasm	0.00347	0.0194	CbGeAlD
Ruxolitinib—CAMK1D—trigeminal ganglion—peripheral nervous system neoplasm	0.00339	0.0189	CbGeAlD
Ruxolitinib—DAPK2—trigeminal ganglion—peripheral nervous system neoplasm	0.00331	0.0185	CbGeAlD
Ruxolitinib—JAK1—parotid gland—peripheral nervous system neoplasm	0.00327	0.0183	CbGeAlD
Ruxolitinib—Contusion—Tretinoin—peripheral nervous system neoplasm	0.00324	0.0105	CcSEcCtD
Ruxolitinib—Contusion—Isotretinoin—peripheral nervous system neoplasm	0.00324	0.0105	CcSEcCtD
Ruxolitinib—DAPK2—parotid gland—peripheral nervous system neoplasm	0.00312	0.0174	CbGeAlD
Ruxolitinib—DAPK3—trigeminal ganglion—peripheral nervous system neoplasm	0.00311	0.0174	CbGeAlD
Ruxolitinib—CLK2—trigeminal ganglion—peripheral nervous system neoplasm	0.00308	0.0172	CbGeAlD
Ruxolitinib—Hypercholesterolaemia—Isotretinoin—peripheral nervous system neoplasm	0.00299	0.00966	CcSEcCtD
Ruxolitinib—Hypercholesterolaemia—Tretinoin—peripheral nervous system neoplasm	0.00299	0.00966	CcSEcCtD
Ruxolitinib—PHKG2—brainstem—peripheral nervous system neoplasm	0.00298	0.0166	CbGeAlD
Ruxolitinib—Bone pain—Topotecan—peripheral nervous system neoplasm	0.00298	0.00961	CcSEcCtD
Ruxolitinib—Bone pain—Isotretinoin—peripheral nervous system neoplasm	0.00295	0.00954	CcSEcCtD
Ruxolitinib—Bone pain—Tretinoin—peripheral nervous system neoplasm	0.00295	0.00954	CcSEcCtD
Ruxolitinib—CLK2—parotid gland—peripheral nervous system neoplasm	0.00291	0.0162	CbGeAlD
Ruxolitinib—HIPK2—brainstem—peripheral nervous system neoplasm	0.00287	0.016	CbGeAlD
Ruxolitinib—NUAK2—trigeminal ganglion—peripheral nervous system neoplasm	0.00277	0.0155	CbGeAlD
Ruxolitinib—NUAK2—parotid gland—peripheral nervous system neoplasm	0.00262	0.0146	CbGeAlD
Ruxolitinib—BMP2K—trigeminal ganglion—peripheral nervous system neoplasm	0.0026	0.0145	CbGeAlD
Ruxolitinib—DYRK1A—brainstem—peripheral nervous system neoplasm	0.00258	0.0144	CbGeAlD
Ruxolitinib—LRRK2—trigeminal ganglion—peripheral nervous system neoplasm	0.00257	0.0144	CbGeAlD
Ruxolitinib—BMPR2—brainstem—peripheral nervous system neoplasm	0.00257	0.0143	CbGeAlD
Ruxolitinib—PRKCE—cerebellum—peripheral nervous system neoplasm	0.00246	0.0137	CbGeAlD
Ruxolitinib—Contusion—Alitretinoin—peripheral nervous system neoplasm	0.00246	0.00793	CcSEcCtD
Ruxolitinib—RPS6KA6—cerebellum—peripheral nervous system neoplasm	0.00236	0.0132	CbGeAlD
Ruxolitinib—MAST1—cerebellum—peripheral nervous system neoplasm	0.00236	0.0132	CbGeAlD
Ruxolitinib—MAP3K7—trigeminal ganglion—peripheral nervous system neoplasm	0.00234	0.013	CbGeAlD
Ruxolitinib—CAMK2G—brainstem—peripheral nervous system neoplasm	0.0023	0.0128	CbGeAlD
Ruxolitinib—TYK2—trigeminal ganglion—peripheral nervous system neoplasm	0.00229	0.0128	CbGeAlD
Ruxolitinib—LRRK2—brainstem—peripheral nervous system neoplasm	0.00228	0.0127	CbGeAlD
Ruxolitinib—Hypercholesterolaemia—Alitretinoin—peripheral nervous system neoplasm	0.00227	0.00732	CcSEcCtD
Ruxolitinib—MKNK2—trigeminal ganglion—peripheral nervous system neoplasm	0.00226	0.0126	CbGeAlD
Ruxolitinib—Bone pain—Alitretinoin—peripheral nervous system neoplasm	0.00224	0.00723	CcSEcCtD
Ruxolitinib—RET—trigeminal ganglion—peripheral nervous system neoplasm	0.00221	0.0123	CbGeAlD
Ruxolitinib—MAP3K7—parotid gland—peripheral nervous system neoplasm	0.0022	0.0123	CbGeAlD
Ruxolitinib—TYK2—parotid gland—peripheral nervous system neoplasm	0.00216	0.0121	CbGeAlD
Ruxolitinib—Bone pain—Vincristine—peripheral nervous system neoplasm	0.00216	0.00696	CcSEcCtD
Ruxolitinib—MKNK2—parotid gland—peripheral nervous system neoplasm	0.00214	0.0119	CbGeAlD
Ruxolitinib—JAK2—trigeminal ganglion—peripheral nervous system neoplasm	0.00209	0.0116	CbGeAlD
Ruxolitinib—Gastrointestinal haemorrhage—Isotretinoin—peripheral nervous system neoplasm	0.00205	0.00663	CcSEcCtD
Ruxolitinib—Gastrointestinal haemorrhage—Tretinoin—peripheral nervous system neoplasm	0.00205	0.00663	CcSEcCtD
Ruxolitinib—MAP3K3—trigeminal ganglion—peripheral nervous system neoplasm	0.00201	0.0112	CbGeAlD
Ruxolitinib—Myelosuppression—Epirubicin—peripheral nervous system neoplasm	0.002	0.00646	CcSEcCtD
Ruxolitinib—PLK1—Chlorambucil—Melphalan—peripheral nervous system neoplasm	0.00197	0.14	CbGdCrCtD
Ruxolitinib—MAP3K3—parotid gland—peripheral nervous system neoplasm	0.0019	0.0106	CbGeAlD
Ruxolitinib—Myelosuppression—Doxorubicin—peripheral nervous system neoplasm	0.00185	0.00598	CcSEcCtD
Ruxolitinib—CAMK1—cerebellum—peripheral nervous system neoplasm	0.00185	0.0103	CbGeAlD
Ruxolitinib—TAOK3—trigeminal ganglion—peripheral nervous system neoplasm	0.00183	0.0102	CbGeAlD
Ruxolitinib—Alanine aminotransferase increased—Topotecan—peripheral nervous system neoplasm	0.00183	0.0059	CcSEcCtD
Ruxolitinib—MARK2—cerebellum—peripheral nervous system neoplasm	0.00179	0.00999	CbGeAlD
Ruxolitinib—TAOK3—parotid gland—peripheral nervous system neoplasm	0.00173	0.00965	CbGeAlD
Ruxolitinib—Pancytopenia—Topotecan—peripheral nervous system neoplasm	0.0017	0.00549	CcSEcCtD
Ruxolitinib—Neutropenia—Topotecan—peripheral nervous system neoplasm	0.00167	0.0054	CcSEcCtD
Ruxolitinib—Pancytopenia—Melphalan—peripheral nervous system neoplasm	0.00166	0.00537	CcSEcCtD
Ruxolitinib—Neutropenia—Tretinoin—peripheral nervous system neoplasm	0.00166	0.00536	CcSEcCtD
Ruxolitinib—Neutropenia—Isotretinoin—peripheral nervous system neoplasm	0.00166	0.00536	CcSEcCtD
Ruxolitinib—TAOK2—cerebellum—peripheral nervous system neoplasm	0.00166	0.00925	CbGeAlD
Ruxolitinib—Neutropenia—Melphalan—peripheral nervous system neoplasm	0.00164	0.00529	CcSEcCtD
Ruxolitinib—Weight increased—Topotecan—peripheral nervous system neoplasm	0.00163	0.00526	CcSEcCtD
Ruxolitinib—TAOK3—brainstem—peripheral nervous system neoplasm	0.00162	0.00905	CbGeAlD
Ruxolitinib—Weight increased—Tretinoin—peripheral nervous system neoplasm	0.00161	0.00522	CcSEcCtD
Ruxolitinib—Weight increased—Isotretinoin—peripheral nervous system neoplasm	0.00161	0.00522	CcSEcCtD
Ruxolitinib—Weight decreased—Tretinoin—peripheral nervous system neoplasm	0.00161	0.00518	CcSEcCtD
Ruxolitinib—Weight decreased—Isotretinoin—peripheral nervous system neoplasm	0.00161	0.00518	CcSEcCtD
Ruxolitinib—Infestation—Topotecan—peripheral nervous system neoplasm	0.00159	0.00515	CcSEcCtD
Ruxolitinib—Infestation NOS—Topotecan—peripheral nervous system neoplasm	0.00159	0.00515	CcSEcCtD
Ruxolitinib—Infestation—Tretinoin—peripheral nervous system neoplasm	0.00158	0.00511	CcSEcCtD
Ruxolitinib—Infestation NOS—Isotretinoin—peripheral nervous system neoplasm	0.00158	0.00511	CcSEcCtD
Ruxolitinib—Infestation—Isotretinoin—peripheral nervous system neoplasm	0.00158	0.00511	CcSEcCtD
Ruxolitinib—Infestation NOS—Tretinoin—peripheral nervous system neoplasm	0.00158	0.00511	CcSEcCtD
Ruxolitinib—Gastrointestinal haemorrhage—Alitretinoin—peripheral nervous system neoplasm	0.00156	0.00503	CcSEcCtD
Ruxolitinib—Urinary tract infection—Isotretinoin—peripheral nervous system neoplasm	0.00154	0.00497	CcSEcCtD
Ruxolitinib—Urinary tract infection—Tretinoin—peripheral nervous system neoplasm	0.00154	0.00497	CcSEcCtD
Ruxolitinib—JAK3—cerebellum—peripheral nervous system neoplasm	0.00152	0.0085	CbGeAlD
Ruxolitinib—JAK1—cerebellum—peripheral nervous system neoplasm	0.00151	0.00844	CbGeAlD
Ruxolitinib—DCLK1—cerebellum—peripheral nervous system neoplasm	0.00151	0.00844	CbGeAlD
Ruxolitinib—Haematuria—Isotretinoin—peripheral nervous system neoplasm	0.00151	0.00487	CcSEcCtD
Ruxolitinib—Haematuria—Tretinoin—peripheral nervous system neoplasm	0.00151	0.00487	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Topotecan—peripheral nervous system neoplasm	0.00151	0.00487	CcSEcCtD
Ruxolitinib—Epistaxis—Topotecan—peripheral nervous system neoplasm	0.0015	0.00486	CcSEcCtD
Ruxolitinib—Epistaxis—Tretinoin—peripheral nervous system neoplasm	0.00149	0.00482	CcSEcCtD
Ruxolitinib—Epistaxis—Isotretinoin—peripheral nervous system neoplasm	0.00149	0.00482	CcSEcCtD
Ruxolitinib—CAMK1D—cerebellum—peripheral nervous system neoplasm	0.00148	0.00824	CbGeAlD
Ruxolitinib—Hepatobiliary disease—Melphalan—peripheral nervous system neoplasm	0.00148	0.00477	CcSEcCtD
Ruxolitinib—PHKG2—cerebellum—peripheral nervous system neoplasm	0.00147	0.00819	CbGeAlD
Ruxolitinib—DAPK2—cerebellum—peripheral nervous system neoplasm	0.00144	0.00805	CbGeAlD
Ruxolitinib—Haemoglobin—Topotecan—peripheral nervous system neoplasm	0.00144	0.00465	CcSEcCtD
Ruxolitinib—Haemorrhage—Topotecan—peripheral nervous system neoplasm	0.00143	0.00462	CcSEcCtD
Ruxolitinib—Haemoglobin—Isotretinoin—peripheral nervous system neoplasm	0.00143	0.00461	CcSEcCtD
Ruxolitinib—Haemoglobin—Tretinoin—peripheral nervous system neoplasm	0.00143	0.00461	CcSEcCtD
Ruxolitinib—STK16—cerebellum—peripheral nervous system neoplasm	0.00142	0.00792	CbGeAlD
Ruxolitinib—Haemorrhage—Tretinoin—peripheral nervous system neoplasm	0.00142	0.00459	CcSEcCtD
Ruxolitinib—Haemorrhage—Isotretinoin—peripheral nervous system neoplasm	0.00142	0.00459	CcSEcCtD
Ruxolitinib—HIPK2—cerebellum—peripheral nervous system neoplasm	0.00141	0.00788	CbGeAlD
Ruxolitinib—Haemoglobin—Melphalan—peripheral nervous system neoplasm	0.00141	0.00455	CcSEcCtD
Ruxolitinib—Haemorrhage—Melphalan—peripheral nervous system neoplasm	0.0014	0.00453	CcSEcCtD
Ruxolitinib—Pancytopenia—Dactinomycin—peripheral nervous system neoplasm	0.00138	0.00445	CcSEcCtD
Ruxolitinib—PLK1—Irinotecan—Topotecan—peripheral nervous system neoplasm	0.00137	0.0976	CbGdCrCtD
Ruxolitinib—DAPK3—cerebellum—peripheral nervous system neoplasm	0.00136	0.00757	CbGeAlD
Ruxolitinib—Neutropenia—Dactinomycin—peripheral nervous system neoplasm	0.00136	0.00438	CcSEcCtD
Ruxolitinib—CLK2—cerebellum—peripheral nervous system neoplasm	0.00135	0.0075	CbGeAlD
Ruxolitinib—Gastrointestinal haemorrhage—Cisplatin—peripheral nervous system neoplasm	0.00133	0.00428	CcSEcCtD
Ruxolitinib—DYRK1A—cerebellum—peripheral nervous system neoplasm	0.00127	0.00709	CbGeAlD
Ruxolitinib—BMPR2—cerebellum—peripheral nervous system neoplasm	0.00127	0.00706	CbGeAlD
Ruxolitinib—Neutropenia—Alitretinoin—peripheral nervous system neoplasm	0.00126	0.00406	CcSEcCtD
Ruxolitinib—Malnutrition—Topotecan—peripheral nervous system neoplasm	0.00125	0.00403	CcSEcCtD
Ruxolitinib—Herpes zoster—Epirubicin—peripheral nervous system neoplasm	0.00125	0.00402	CcSEcCtD
Ruxolitinib—Malnutrition—Isotretinoin—peripheral nervous system neoplasm	0.00124	0.00399	CcSEcCtD
Ruxolitinib—Malnutrition—Tretinoin—peripheral nervous system neoplasm	0.00124	0.00399	CcSEcCtD
Ruxolitinib—Pancytopenia—Vincristine—peripheral nervous system neoplasm	0.00123	0.00397	CcSEcCtD
Ruxolitinib—Weight increased—Alitretinoin—peripheral nervous system neoplasm	0.00122	0.00395	CcSEcCtD
Ruxolitinib—Flatulence—Tretinoin—peripheral nervous system neoplasm	0.00122	0.00393	CcSEcCtD
Ruxolitinib—Flatulence—Isotretinoin—peripheral nervous system neoplasm	0.00122	0.00393	CcSEcCtD
Ruxolitinib—Weight decreased—Alitretinoin—peripheral nervous system neoplasm	0.00122	0.00393	CcSEcCtD
Ruxolitinib—Neutropenia—Vincristine—peripheral nervous system neoplasm	0.00121	0.00391	CcSEcCtD
Ruxolitinib—NUAK2—cerebellum—peripheral nervous system neoplasm	0.00121	0.00675	CbGeAlD
Ruxolitinib—Infestation NOS—Alitretinoin—peripheral nervous system neoplasm	0.0012	0.00387	CcSEcCtD
Ruxolitinib—Infestation—Alitretinoin—peripheral nervous system neoplasm	0.0012	0.00387	CcSEcCtD
Ruxolitinib—Weight decreased—Vincristine—peripheral nervous system neoplasm	0.00117	0.00379	CcSEcCtD
Ruxolitinib—Urinary tract infection—Alitretinoin—peripheral nervous system neoplasm	0.00117	0.00376	CcSEcCtD
Ruxolitinib—Herpes zoster—Doxorubicin—peripheral nervous system neoplasm	0.00115	0.00372	CcSEcCtD
Ruxolitinib—Anaemia—Topotecan—peripheral nervous system neoplasm	0.00115	0.00372	CcSEcCtD
Ruxolitinib—Haematuria—Alitretinoin—peripheral nervous system neoplasm	0.00114	0.00369	CcSEcCtD
Ruxolitinib—Anaemia—Tretinoin—peripheral nervous system neoplasm	0.00114	0.00369	CcSEcCtD
Ruxolitinib—Anaemia—Isotretinoin—peripheral nervous system neoplasm	0.00114	0.00369	CcSEcCtD
Ruxolitinib—BMP2K—cerebellum—peripheral nervous system neoplasm	0.00113	0.00632	CbGeAlD
Ruxolitinib—CAMK2G—cerebellum—peripheral nervous system neoplasm	0.00113	0.00632	CbGeAlD
Ruxolitinib—Epistaxis—Alitretinoin—peripheral nervous system neoplasm	0.00113	0.00365	CcSEcCtD
Ruxolitinib—Anaemia—Melphalan—peripheral nervous system neoplasm	0.00113	0.00364	CcSEcCtD
Ruxolitinib—LRRK2—cerebellum—peripheral nervous system neoplasm	0.00112	0.00626	CbGeAlD
Ruxolitinib—Pancytopenia—Cisplatin—peripheral nervous system neoplasm	0.00109	0.00351	CcSEcCtD
Ruxolitinib—Haemoglobin—Alitretinoin—peripheral nervous system neoplasm	0.00108	0.00349	CcSEcCtD
Ruxolitinib—Haemorrhage—Alitretinoin—peripheral nervous system neoplasm	0.00108	0.00348	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Etoposide—peripheral nervous system neoplasm	0.00107	0.00346	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Topotecan—peripheral nervous system neoplasm	0.00105	0.0034	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Isotretinoin—peripheral nervous system neoplasm	0.00105	0.00338	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Tretinoin—peripheral nervous system neoplasm	0.00105	0.00338	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Melphalan—peripheral nervous system neoplasm	0.00103	0.00333	CcSEcCtD
Ruxolitinib—MAP3K2—cerebellum—peripheral nervous system neoplasm	0.00103	0.00574	CbGeAlD
Ruxolitinib—MAP3K7—cerebellum—peripheral nervous system neoplasm	0.00102	0.00569	CbGeAlD
Ruxolitinib—Infection—Topotecan—peripheral nervous system neoplasm	0.00101	0.00326	CcSEcCtD
Ruxolitinib—Infection—Isotretinoin—peripheral nervous system neoplasm	0.001	0.00324	CcSEcCtD
Ruxolitinib—Infection—Tretinoin—peripheral nervous system neoplasm	0.001	0.00324	CcSEcCtD
Ruxolitinib—TYK2—cerebellum—peripheral nervous system neoplasm	0.001	0.00558	CbGeAlD
Ruxolitinib—Nervous system disorder—Topotecan—peripheral nervous system neoplasm	0.000997	0.00322	CcSEcCtD
Ruxolitinib—Pancytopenia—Etoposide—peripheral nervous system neoplasm	0.000997	0.00322	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Topotecan—peripheral nervous system neoplasm	0.000996	0.00322	CcSEcCtD
Ruxolitinib—Nervous system disorder—Isotretinoin—peripheral nervous system neoplasm	0.000989	0.0032	CcSEcCtD
Ruxolitinib—Nervous system disorder—Tretinoin—peripheral nervous system neoplasm	0.000989	0.0032	CcSEcCtD
Ruxolitinib—Infection—Melphalan—peripheral nervous system neoplasm	0.000989	0.0032	CcSEcCtD
Ruxolitinib—IRAK1—cerebellum—peripheral nervous system neoplasm	0.000988	0.00551	CbGeAlD
Ruxolitinib—MKNK2—cerebellum—peripheral nervous system neoplasm	0.000988	0.00551	CbGeAlD
Ruxolitinib—Skin disorder—Topotecan—peripheral nervous system neoplasm	0.000988	0.00319	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Isotretinoin—peripheral nervous system neoplasm	0.000988	0.00319	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Tretinoin—peripheral nervous system neoplasm	0.000988	0.00319	CcSEcCtD
Ruxolitinib—Neutropenia—Etoposide—peripheral nervous system neoplasm	0.000981	0.00317	CcSEcCtD
Ruxolitinib—Skin disorder—Tretinoin—peripheral nervous system neoplasm	0.00098	0.00317	CcSEcCtD
Ruxolitinib—Skin disorder—Isotretinoin—peripheral nervous system neoplasm	0.00098	0.00317	CcSEcCtD
Ruxolitinib—Bone pain—Epirubicin—peripheral nervous system neoplasm	0.000979	0.00316	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Melphalan—peripheral nervous system neoplasm	0.000975	0.00315	CcSEcCtD
Ruxolitinib—Skin disorder—Melphalan—peripheral nervous system neoplasm	0.000967	0.00312	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Cisplatin—peripheral nervous system neoplasm	0.000966	0.00312	CcSEcCtD
Ruxolitinib—RET—cerebellum—peripheral nervous system neoplasm	0.000964	0.00537	CbGeAlD
Ruxolitinib—Malnutrition—Alitretinoin—peripheral nervous system neoplasm	0.000937	0.00303	CcSEcCtD
Ruxolitinib—Infestation—Etoposide—peripheral nervous system neoplasm	0.000936	0.00302	CcSEcCtD
Ruxolitinib—Infestation NOS—Etoposide—peripheral nervous system neoplasm	0.000936	0.00302	CcSEcCtD
Ruxolitinib—Anaemia—Dactinomycin—peripheral nervous system neoplasm	0.000934	0.00302	CcSEcCtD
Ruxolitinib—Flatulence—Alitretinoin—peripheral nervous system neoplasm	0.000923	0.00298	CcSEcCtD
Ruxolitinib—JAK2—cerebellum—peripheral nervous system neoplasm	0.000911	0.00508	CbGeAlD
Ruxolitinib—Bone pain—Doxorubicin—peripheral nervous system neoplasm	0.000906	0.00293	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Etoposide—peripheral nervous system neoplasm	0.000885	0.00286	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Topotecan—peripheral nervous system neoplasm	0.000878	0.00284	CcSEcCtD
Ruxolitinib—MAP3K3—cerebellum—peripheral nervous system neoplasm	0.000878	0.0049	CbGeAlD
Ruxolitinib—Fatigue—Topotecan—peripheral nervous system neoplasm	0.000877	0.00283	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Tretinoin—peripheral nervous system neoplasm	0.000871	0.00281	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Isotretinoin—peripheral nervous system neoplasm	0.000871	0.00281	CcSEcCtD
Ruxolitinib—Fatigue—Isotretinoin—peripheral nervous system neoplasm	0.00087	0.00281	CcSEcCtD
Ruxolitinib—Fatigue—Tretinoin—peripheral nervous system neoplasm	0.00087	0.00281	CcSEcCtD
Ruxolitinib—Anaemia—Alitretinoin—peripheral nervous system neoplasm	0.000866	0.0028	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Melphalan—peripheral nervous system neoplasm	0.00086	0.00278	CcSEcCtD
Ruxolitinib—Fatigue—Melphalan—peripheral nervous system neoplasm	0.000859	0.00277	CcSEcCtD
Ruxolitinib—Anaemia—Vincristine—peripheral nervous system neoplasm	0.000834	0.0027	CcSEcCtD
Ruxolitinib—Infection—Dactinomycin—peripheral nervous system neoplasm	0.000819	0.00265	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Dactinomycin—peripheral nervous system neoplasm	0.000807	0.00261	CcSEcCtD
Ruxolitinib—Body temperature increased—Topotecan—peripheral nervous system neoplasm	0.000804	0.0026	CcSEcCtD
Ruxolitinib—TAOK3—cerebellum—peripheral nervous system neoplasm	0.0008	0.00446	CbGeAlD
Ruxolitinib—Malnutrition—Cisplatin—peripheral nervous system neoplasm	0.000798	0.00258	CcSEcCtD
Ruxolitinib—Body temperature increased—Tretinoin—peripheral nervous system neoplasm	0.000798	0.00258	CcSEcCtD
Ruxolitinib—Body temperature increased—Isotretinoin—peripheral nervous system neoplasm	0.000798	0.00258	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Alitretinoin—peripheral nervous system neoplasm	0.000792	0.00256	CcSEcCtD
Ruxolitinib—Flatulence—Cisplatin—peripheral nervous system neoplasm	0.000787	0.00254	CcSEcCtD
Ruxolitinib—Infection—Alitretinoin—peripheral nervous system neoplasm	0.00076	0.00245	CcSEcCtD
Ruxolitinib—Nervous system disorder—Alitretinoin—peripheral nervous system neoplasm	0.00075	0.00242	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Alitretinoin—peripheral nervous system neoplasm	0.000749	0.00242	CcSEcCtD
Ruxolitinib—Skin disorder—Alitretinoin—peripheral nervous system neoplasm	0.000743	0.0024	CcSEcCtD
Ruxolitinib—Anaemia—Cisplatin—peripheral nervous system neoplasm	0.000738	0.00238	CcSEcCtD
Ruxolitinib—Infection—Vincristine—peripheral nervous system neoplasm	0.000732	0.00236	CcSEcCtD
Ruxolitinib—Asthenia—Topotecan—peripheral nervous system neoplasm	0.00073	0.00236	CcSEcCtD
Ruxolitinib—Asthenia—Isotretinoin—peripheral nervous system neoplasm	0.000724	0.00234	CcSEcCtD
Ruxolitinib—Asthenia—Tretinoin—peripheral nervous system neoplasm	0.000724	0.00234	CcSEcCtD
Ruxolitinib—Nervous system disorder—Vincristine—peripheral nervous system neoplasm	0.000723	0.00233	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Vincristine—peripheral nervous system neoplasm	0.000721	0.00233	CcSEcCtD
Ruxolitinib—Pruritus—Topotecan—peripheral nervous system neoplasm	0.00072	0.00232	CcSEcCtD
Ruxolitinib—Asthenia—Melphalan—peripheral nervous system neoplasm	0.000714	0.00231	CcSEcCtD
Ruxolitinib—Pruritus—Isotretinoin—peripheral nervous system neoplasm	0.000714	0.00231	CcSEcCtD
Ruxolitinib—Pruritus—Tretinoin—peripheral nervous system neoplasm	0.000714	0.00231	CcSEcCtD
Ruxolitinib—Fatigue—Dactinomycin—peripheral nervous system neoplasm	0.000711	0.0023	CcSEcCtD
Ruxolitinib—Pruritus—Melphalan—peripheral nervous system neoplasm	0.000705	0.00228	CcSEcCtD
Ruxolitinib—Gastrointestinal haemorrhage—Epirubicin—peripheral nervous system neoplasm	0.000681	0.0022	CcSEcCtD
Ruxolitinib—Anaemia—Etoposide—peripheral nervous system neoplasm	0.000676	0.00218	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—peripheral nervous system neoplasm	0.000675	0.00218	CcSEcCtD
Ruxolitinib—Dizziness—Topotecan—peripheral nervous system neoplasm	0.000673	0.00217	CcSEcCtD
Ruxolitinib—Dizziness—Tretinoin—peripheral nervous system neoplasm	0.000667	0.00216	CcSEcCtD
Ruxolitinib—Dizziness—Isotretinoin—peripheral nervous system neoplasm	0.000667	0.00216	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Alitretinoin—peripheral nervous system neoplasm	0.00066	0.00213	CcSEcCtD
Ruxolitinib—Fatigue—Alitretinoin—peripheral nervous system neoplasm	0.000659	0.00213	CcSEcCtD
Ruxolitinib—Body temperature increased—Dactinomycin—peripheral nervous system neoplasm	0.000652	0.00211	CcSEcCtD
Ruxolitinib—Infection—Cisplatin—peripheral nervous system neoplasm	0.000647	0.00209	CcSEcCtD
Ruxolitinib—Nervous system disorder—Cisplatin—peripheral nervous system neoplasm	0.000639	0.00206	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Cisplatin—peripheral nervous system neoplasm	0.000638	0.00206	CcSEcCtD
Ruxolitinib—Headache—Topotecan—peripheral nervous system neoplasm	0.000637	0.00206	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Vincristine—peripheral nervous system neoplasm	0.000636	0.00205	CcSEcCtD
Ruxolitinib—Fatigue—Vincristine—peripheral nervous system neoplasm	0.000635	0.00205	CcSEcCtD
Ruxolitinib—Skin disorder—Cisplatin—peripheral nervous system neoplasm	0.000633	0.00204	CcSEcCtD
Ruxolitinib—Headache—Tretinoin—peripheral nervous system neoplasm	0.000632	0.00204	CcSEcCtD
Ruxolitinib—Headache—Isotretinoin—peripheral nervous system neoplasm	0.000632	0.00204	CcSEcCtD
Ruxolitinib—Gastrointestinal haemorrhage—Doxorubicin—peripheral nervous system neoplasm	0.00063	0.00203	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—peripheral nervous system neoplasm	0.000618	0.002	CcSEcCtD
Ruxolitinib—Body temperature increased—Alitretinoin—peripheral nervous system neoplasm	0.000604	0.00195	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Epirubicin—peripheral nervous system neoplasm	0.0006	0.00194	CcSEcCtD
Ruxolitinib—Infection—Etoposide—peripheral nervous system neoplasm	0.000593	0.00192	CcSEcCtD
Ruxolitinib—Asthenia—Dactinomycin—peripheral nervous system neoplasm	0.000592	0.00191	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Etoposide—peripheral nervous system neoplasm	0.000584	0.00189	CcSEcCtD
Ruxolitinib—Body temperature increased—Vincristine—peripheral nervous system neoplasm	0.000582	0.00188	CcSEcCtD
Ruxolitinib—Skin disorder—Etoposide—peripheral nervous system neoplasm	0.00058	0.00187	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	0.000562	0.00182	CcSEcCtD
Ruxolitinib—Pancytopenia—Epirubicin—peripheral nervous system neoplasm	0.000559	0.0018	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	0.000555	0.00179	CcSEcCtD
Ruxolitinib—Neutropenia—Epirubicin—peripheral nervous system neoplasm	0.00055	0.00178	CcSEcCtD
Ruxolitinib—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.000549	0.00177	CcSEcCtD
Ruxolitinib—Pruritus—Alitretinoin—peripheral nervous system neoplasm	0.000541	0.00175	CcSEcCtD
Ruxolitinib—Weight increased—Epirubicin—peripheral nervous system neoplasm	0.000535	0.00173	CcSEcCtD
Ruxolitinib—Weight decreased—Epirubicin—peripheral nervous system neoplasm	0.000532	0.00172	CcSEcCtD
Ruxolitinib—Asthenia—Vincristine—peripheral nervous system neoplasm	0.000529	0.00171	CcSEcCtD
Ruxolitinib—Infestation NOS—Epirubicin—peripheral nervous system neoplasm	0.000525	0.00169	CcSEcCtD
Ruxolitinib—Infestation—Epirubicin—peripheral nervous system neoplasm	0.000525	0.00169	CcSEcCtD
Ruxolitinib—Pancytopenia—Doxorubicin—peripheral nervous system neoplasm	0.000517	0.00167	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	0.000515	0.00166	CcSEcCtD
Ruxolitinib—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	0.000515	0.00166	CcSEcCtD
Ruxolitinib—Fatigue—Etoposide—peripheral nervous system neoplasm	0.000515	0.00166	CcSEcCtD
Ruxolitinib—PLK1—Teniposide—Etoposide—peripheral nervous system neoplasm	0.000513	0.0366	CbGdCrCtD
Ruxolitinib—PLK4—Teniposide—Etoposide—peripheral nervous system neoplasm	0.000513	0.0366	CbGdCrCtD
Ruxolitinib—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	0.00051	0.00165	CcSEcCtD
Ruxolitinib—Neutropenia—Doxorubicin—peripheral nervous system neoplasm	0.000509	0.00164	CcSEcCtD
Ruxolitinib—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.000506	0.00163	CcSEcCtD
Ruxolitinib—Haematuria—Epirubicin—peripheral nervous system neoplasm	0.0005	0.00162	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Epirubicin—peripheral nervous system neoplasm	0.000496	0.0016	CcSEcCtD
Ruxolitinib—Weight increased—Doxorubicin—peripheral nervous system neoplasm	0.000495	0.0016	CcSEcCtD
Ruxolitinib—Epistaxis—Epirubicin—peripheral nervous system neoplasm	0.000495	0.0016	CcSEcCtD
Ruxolitinib—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	0.000492	0.00159	CcSEcCtD
Ruxolitinib—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000487	0.00157	CcSEcCtD
Ruxolitinib—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	0.000485	0.00157	CcSEcCtD
Ruxolitinib—Infestation—Doxorubicin—peripheral nervous system neoplasm	0.000485	0.00157	CcSEcCtD
Ruxolitinib—Headache—Alitretinoin—peripheral nervous system neoplasm	0.000479	0.00155	CcSEcCtD
Ruxolitinib—Haemoglobin—Epirubicin—peripheral nervous system neoplasm	0.000473	0.00153	CcSEcCtD
Ruxolitinib—Body temperature increased—Etoposide—peripheral nervous system neoplasm	0.000472	0.00152	CcSEcCtD
Ruxolitinib—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000472	0.00152	CcSEcCtD
Ruxolitinib—Haemorrhage—Epirubicin—peripheral nervous system neoplasm	0.000471	0.00152	CcSEcCtD
Ruxolitinib—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.000467	0.00151	CcSEcCtD
Ruxolitinib—Haematuria—Doxorubicin—peripheral nervous system neoplasm	0.000463	0.00149	CcSEcCtD
Ruxolitinib—Headache—Vincristine—peripheral nervous system neoplasm	0.000462	0.00149	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Doxorubicin—peripheral nervous system neoplasm	0.000459	0.00148	CcSEcCtD
Ruxolitinib—Epistaxis—Doxorubicin—peripheral nervous system neoplasm	0.000458	0.00148	CcSEcCtD
Ruxolitinib—Haemoglobin—Doxorubicin—peripheral nervous system neoplasm	0.000438	0.00141	CcSEcCtD
Ruxolitinib—Haemorrhage—Doxorubicin—peripheral nervous system neoplasm	0.000436	0.00141	CcSEcCtD
Ruxolitinib—Asthenia—Etoposide—peripheral nervous system neoplasm	0.000428	0.00138	CcSEcCtD
Ruxolitinib—Pruritus—Etoposide—peripheral nervous system neoplasm	0.000422	0.00136	CcSEcCtD
Ruxolitinib—Malnutrition—Epirubicin—peripheral nervous system neoplasm	0.00041	0.00132	CcSEcCtD
Ruxolitinib—Flatulence—Epirubicin—peripheral nervous system neoplasm	0.000404	0.0013	CcSEcCtD
Ruxolitinib—Dizziness—Etoposide—peripheral nervous system neoplasm	0.000395	0.00127	CcSEcCtD
Ruxolitinib—DYRK1A—Doxorubicin—Epirubicin—peripheral nervous system neoplasm	0.000392	0.0279	CbGdCrCtD
Ruxolitinib—DYRK1A—Idarubicin—Epirubicin—peripheral nervous system neoplasm	0.000392	0.0279	CbGdCrCtD
Ruxolitinib—DYRK1A—Daunorubicin—Epirubicin—peripheral nervous system neoplasm	0.000392	0.0279	CbGdCrCtD
Ruxolitinib—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	0.000379	0.00123	CcSEcCtD
Ruxolitinib—Anaemia—Epirubicin—peripheral nervous system neoplasm	0.000379	0.00122	CcSEcCtD
Ruxolitinib—Headache—Etoposide—peripheral nervous system neoplasm	0.000374	0.00121	CcSEcCtD
Ruxolitinib—Flatulence—Doxorubicin—peripheral nervous system neoplasm	0.000374	0.00121	CcSEcCtD
Ruxolitinib—DYRK1A—Daunorubicin—Doxorubicin—peripheral nervous system neoplasm	0.000363	0.0258	CbGdCrCtD
Ruxolitinib—DYRK1A—Idarubicin—Doxorubicin—peripheral nervous system neoplasm	0.000363	0.0258	CbGdCrCtD
Ruxolitinib—DYRK1A—Epirubicin—Doxorubicin—peripheral nervous system neoplasm	0.000363	0.0258	CbGdCrCtD
Ruxolitinib—Anaemia—Doxorubicin—peripheral nervous system neoplasm	0.000351	0.00113	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	0.000347	0.00112	CcSEcCtD
Ruxolitinib—Infection—Epirubicin—peripheral nervous system neoplasm	0.000332	0.00107	CcSEcCtD
Ruxolitinib—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	0.000328	0.00106	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	0.000328	0.00106	CcSEcCtD
Ruxolitinib—Skin disorder—Epirubicin—peripheral nervous system neoplasm	0.000325	0.00105	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	0.000321	0.00104	CcSEcCtD
Ruxolitinib—Infection—Doxorubicin—peripheral nervous system neoplasm	0.000308	0.000993	CcSEcCtD
Ruxolitinib—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	0.000304	0.000981	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	0.000303	0.000979	CcSEcCtD
Ruxolitinib—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	0.000301	0.000971	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000289	0.000933	CcSEcCtD
Ruxolitinib—Fatigue—Epirubicin—peripheral nervous system neoplasm	0.000288	0.000932	CcSEcCtD
Ruxolitinib—PLK1—Daunorubicin—Epirubicin—peripheral nervous system neoplasm	0.000268	0.0191	CbGdCrCtD
Ruxolitinib—PLK4—Doxorubicin—Epirubicin—peripheral nervous system neoplasm	0.000268	0.0191	CbGdCrCtD
Ruxolitinib—PLK1—Idarubicin—Epirubicin—peripheral nervous system neoplasm	0.000268	0.0191	CbGdCrCtD
Ruxolitinib—PLK4—Idarubicin—Epirubicin—peripheral nervous system neoplasm	0.000268	0.0191	CbGdCrCtD
Ruxolitinib—PLK1—Doxorubicin—Epirubicin—peripheral nervous system neoplasm	0.000268	0.0191	CbGdCrCtD
Ruxolitinib—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000267	0.000863	CcSEcCtD
Ruxolitinib—Fatigue—Doxorubicin—peripheral nervous system neoplasm	0.000267	0.000862	CcSEcCtD
Ruxolitinib—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	0.000264	0.000854	CcSEcCtD
Ruxolitinib—PLK4—Idarubicin—Doxorubicin—peripheral nervous system neoplasm	0.000248	0.0176	CbGdCrCtD
Ruxolitinib—PLK1—Daunorubicin—Doxorubicin—peripheral nervous system neoplasm	0.000248	0.0176	CbGdCrCtD
Ruxolitinib—PLK1—Epirubicin—Doxorubicin—peripheral nervous system neoplasm	0.000248	0.0176	CbGdCrCtD
Ruxolitinib—PLK1—Idarubicin—Doxorubicin—peripheral nervous system neoplasm	0.000248	0.0176	CbGdCrCtD
Ruxolitinib—PLK4—Epirubicin—Doxorubicin—peripheral nervous system neoplasm	0.000248	0.0176	CbGdCrCtD
Ruxolitinib—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	0.000245	0.00079	CcSEcCtD
Ruxolitinib—Asthenia—Epirubicin—peripheral nervous system neoplasm	0.00024	0.000775	CcSEcCtD
Ruxolitinib—Pruritus—Epirubicin—peripheral nervous system neoplasm	0.000237	0.000765	CcSEcCtD
Ruxolitinib—Asthenia—Doxorubicin—peripheral nervous system neoplasm	0.000222	0.000717	CcSEcCtD
Ruxolitinib—Dizziness—Epirubicin—peripheral nervous system neoplasm	0.000221	0.000715	CcSEcCtD
Ruxolitinib—Pruritus—Doxorubicin—peripheral nervous system neoplasm	0.000219	0.000707	CcSEcCtD
Ruxolitinib—Headache—Epirubicin—peripheral nervous system neoplasm	0.00021	0.000677	CcSEcCtD
Ruxolitinib—Dizziness—Doxorubicin—peripheral nervous system neoplasm	0.000205	0.000661	CcSEcCtD
Ruxolitinib—Headache—Doxorubicin—peripheral nervous system neoplasm	0.000194	0.000626	CcSEcCtD
Ruxolitinib—JAK2—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—peripheral nervous system neoplasm	2.7e-05	5.43e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—GNAS—peripheral nervous system neoplasm	2.7e-05	5.42e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	2.68e-05	5.4e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—SLC2A1—peripheral nervous system neoplasm	2.68e-05	5.39e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—PTPN11—peripheral nervous system neoplasm	2.68e-05	5.38e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—ERBB2—peripheral nervous system neoplasm	2.66e-05	5.36e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Innate Immune System—AKT1—peripheral nervous system neoplasm	2.66e-05	5.35e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	2.66e-05	5.35e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PPIP5K2—peripheral nervous system neoplasm	2.66e-05	5.35e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Axon guidance—NRAS—peripheral nervous system neoplasm	2.66e-05	5.34e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—GNAS—peripheral nervous system neoplasm	2.65e-05	5.33e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	2.64e-05	5.32e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	2.63e-05	5.28e-05	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—MYC—peripheral nervous system neoplasm	2.62e-05	5.27e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	2.58e-05	5.19e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	2.58e-05	5.19e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling by NGF—AKT1—peripheral nervous system neoplasm	2.58e-05	5.18e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Axon guidance—HRAS—peripheral nervous system neoplasm	2.56e-05	5.16e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	2.55e-05	5.14e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Hemostasis—TP53—peripheral nervous system neoplasm	2.54e-05	5.11e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by NGF—AKT1—peripheral nervous system neoplasm	2.5e-05	5.03e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—NRAS—peripheral nervous system neoplasm	2.5e-05	5.03e-05	CbGpPWpGaD
Ruxolitinib—PHKG2—Disease—HRAS—peripheral nervous system neoplasm	2.5e-05	5.02e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Hemostasis—AKT1—peripheral nervous system neoplasm	2.5e-05	5.02e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—ERBB2—peripheral nervous system neoplasm	2.49e-05	5.01e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Developmental Biology—HRAS—peripheral nervous system neoplasm	2.48e-05	4.99e-05	CbGpPWpGaD
Ruxolitinib—JAK2—NGF signalling via TRKA from the plasma membrane—AKT1—peripheral nervous system neoplasm	2.46e-05	4.96e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—MYC—peripheral nervous system neoplasm	2.46e-05	4.95e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Disease—AKT1—peripheral nervous system neoplasm	2.44e-05	4.9e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Developmental Biology—HRAS—peripheral nervous system neoplasm	2.44e-05	4.9e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Hemostasis—HRAS—peripheral nervous system neoplasm	2.43e-05	4.89e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—NRAS—peripheral nervous system neoplasm	2.4e-05	4.83e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—NRAS—peripheral nervous system neoplasm	2.39e-05	4.81e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—KNG1—peripheral nervous system neoplasm	2.34e-05	4.72e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	2.34e-05	4.71e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Platelet activation, signaling and aggregation—AKT1—peripheral nervous system neoplasm	2.33e-05	4.69e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—ERBB2—peripheral nervous system neoplasm	2.29e-05	4.61e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—KNG1—peripheral nervous system neoplasm	2.28e-05	4.58e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—NRAS—peripheral nervous system neoplasm	2.27e-05	4.58e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	2.23e-05	4.5e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling by Wnt—AKT1—peripheral nervous system neoplasm	2.23e-05	4.49e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—MYC—peripheral nervous system neoplasm	2.23e-05	4.48e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—HGF—peripheral nervous system neoplasm	2.22e-05	4.47e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	2.22e-05	4.46e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—NRAS—peripheral nervous system neoplasm	2.22e-05	4.46e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—NRAS—peripheral nervous system neoplasm	2.21e-05	4.44e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—KNG1—peripheral nervous system neoplasm	2.21e-05	4.44e-05	CbGpPWpGaD
Ruxolitinib—PHKG2—Disease—AKT1—peripheral nervous system neoplasm	2.2e-05	4.44e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—PTPN11—peripheral nervous system neoplasm	2.2e-05	4.43e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—ERBB2—peripheral nervous system neoplasm	2.2e-05	4.43e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—NRAS—peripheral nervous system neoplasm	2.2e-05	4.42e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Innate Immune System—HRAS—peripheral nervous system neoplasm	2.19e-05	4.4e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Developmental Biology—AKT1—peripheral nervous system neoplasm	2.19e-05	4.4e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Cytokine Signaling in Immune system—HRAS—peripheral nervous system neoplasm	2.18e-05	4.39e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	2.18e-05	4.38e-05	CbGpPWpGaD
Ruxolitinib—PRKG2—Metabolism—AKT1—peripheral nervous system neoplasm	2.17e-05	4.37e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	2.17e-05	4.36e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Developmental Biology—AKT1—peripheral nervous system neoplasm	2.15e-05	4.33e-05	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.15e-05	4.33e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—NRAS—peripheral nervous system neoplasm	2.15e-05	4.32e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by NGF—HRAS—peripheral nervous system neoplasm	2.15e-05	4.32e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Hemostasis—AKT1—peripheral nervous system neoplasm	2.15e-05	4.32e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—NRAS—peripheral nervous system neoplasm	2.14e-05	4.31e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—PTPN11—peripheral nervous system neoplasm	2.14e-05	4.3e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—ERBB2—peripheral nervous system neoplasm	2.11e-05	4.25e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	2.1e-05	4.23e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—PTPN11—peripheral nervous system neoplasm	2.07e-05	4.17e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—MYC—peripheral nervous system neoplasm	2.06e-05	4.15e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—NRAS—peripheral nervous system neoplasm	2.06e-05	4.14e-05	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.06e-05	4.14e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—GNAS—peripheral nervous system neoplasm	2.05e-05	4.12e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.04e-05	4.1e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—NRAS—peripheral nervous system neoplasm	2.03e-05	4.07e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.02e-05	4.07e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	2.02e-05	4.06e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—GNAS—peripheral nervous system neoplasm	1.99e-05	4e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—PTPN11—peripheral nervous system neoplasm	1.98e-05	3.97e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Axon guidance—HRAS—peripheral nervous system neoplasm	1.94e-05	3.91e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.93e-05	3.89e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Innate Immune System—AKT1—peripheral nervous system neoplasm	1.93e-05	3.89e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—GNAS—peripheral nervous system neoplasm	1.93e-05	3.88e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.92e-05	3.87e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	1.91e-05	3.84e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by NGF—AKT1—peripheral nervous system neoplasm	1.9e-05	3.81e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—NRAS—peripheral nervous system neoplasm	1.9e-05	3.81e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	1.88e-05	3.77e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.87e-05	3.77e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.87e-05	3.76e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—NRAS—peripheral nervous system neoplasm	1.86e-05	3.74e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.85e-05	3.72e-05	CbGpPWpGaD
Ruxolitinib—PHKG2—Metabolism—AKT1—peripheral nervous system neoplasm	1.85e-05	3.71e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.84e-05	3.71e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—HRAS—peripheral nervous system neoplasm	1.83e-05	3.68e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.83e-05	3.68e-05	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.82e-05	3.65e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—HSD17B12—peripheral nervous system neoplasm	1.79e-05	3.61e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	1.77e-05	3.57e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—HRAS—peripheral nervous system neoplasm	1.76e-05	3.53e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.75e-05	3.52e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—NRAS—peripheral nervous system neoplasm	1.74e-05	3.51e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—ERBB2—peripheral nervous system neoplasm	1.74e-05	3.5e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—KNG1—peripheral nervous system neoplasm	1.72e-05	3.47e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.72e-05	3.46e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.71e-05	3.43e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.7e-05	3.41e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—ERBB2—peripheral nervous system neoplasm	1.69e-05	3.4e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—NRAS—peripheral nervous system neoplasm	1.67e-05	3.37e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—HRAS—peripheral nervous system neoplasm	1.66e-05	3.35e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	1.64e-05	3.31e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—ERBB2—peripheral nervous system neoplasm	1.64e-05	3.3e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.62e-05	3.26e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—PTPN11—peripheral nervous system neoplasm	1.62e-05	3.26e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—HRAS—peripheral nervous system neoplasm	1.62e-05	3.26e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—HRAS—peripheral nervous system neoplasm	1.62e-05	3.25e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—AKT1—peripheral nervous system neoplasm	1.62e-05	3.25e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—NRAS—peripheral nervous system neoplasm	1.61e-05	3.24e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—HRAS—peripheral nervous system neoplasm	1.61e-05	3.24e-05	CbGpPWpGaD
Ruxolitinib—JAK3—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.58e-05	3.17e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—HRAS—peripheral nervous system neoplasm	1.57e-05	3.16e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—HRAS—peripheral nervous system neoplasm	1.57e-05	3.15e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.56e-05	3.14e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—ERBB2—peripheral nervous system neoplasm	1.56e-05	3.14e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.55e-05	3.12e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—AKT1—peripheral nervous system neoplasm	1.55e-05	3.12e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.54e-05	3.11e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—GNAS—peripheral nervous system neoplasm	1.51e-05	3.03e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	1.5e-05	3.03e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—MYC—peripheral nervous system neoplasm	1.5e-05	3.01e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PTPN11—peripheral nervous system neoplasm	1.5e-05	3.01e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—HRAS—peripheral nervous system neoplasm	1.48e-05	2.98e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.48e-05	2.98e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—AKT1—peripheral nervous system neoplasm	1.47e-05	2.96e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.46e-05	2.93e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.45e-05	2.91e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.43e-05	2.88e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—AKT1—peripheral nervous system neoplasm	1.43e-05	2.88e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—AKT1—peripheral nervous system neoplasm	1.43e-05	2.87e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.42e-05	2.87e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—TP53—peripheral nervous system neoplasm	1.42e-05	2.86e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—AKT1—peripheral nervous system neoplasm	1.42e-05	2.86e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	1.41e-05	2.83e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.4e-05	2.81e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—AKT1—peripheral nervous system neoplasm	1.39e-05	2.79e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—HRAS—peripheral nervous system neoplasm	1.39e-05	2.79e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—AKT1—peripheral nervous system neoplasm	1.38e-05	2.78e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.38e-05	2.78e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.37e-05	2.76e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—HRAS—peripheral nervous system neoplasm	1.36e-05	2.74e-05	CbGpPWpGaD
Ruxolitinib—JAK1—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.36e-05	2.73e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.34e-05	2.7e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.34e-05	2.7e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.33e-05	2.68e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	1.33e-05	2.67e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—NRAS—peripheral nervous system neoplasm	1.32e-05	2.67e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.32e-05	2.66e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.31e-05	2.63e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—AKT1—peripheral nervous system neoplasm	1.31e-05	2.63e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GNS—peripheral nervous system neoplasm	1.3e-05	2.61e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—NRAS—peripheral nervous system neoplasm	1.29e-05	2.59e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—ERBB2—peripheral nervous system neoplasm	1.28e-05	2.58e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—HRAS—peripheral nervous system neoplasm	1.27e-05	2.56e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—NRAS—peripheral nervous system neoplasm	1.25e-05	2.51e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—NME1—peripheral nervous system neoplasm	1.24e-05	2.5e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.23e-05	2.48e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—HRAS—peripheral nervous system neoplasm	1.22e-05	2.46e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—AKT1—peripheral nervous system neoplasm	1.22e-05	2.46e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.22e-05	2.45e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.21e-05	2.44e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—AKT1—peripheral nervous system neoplasm	1.2e-05	2.42e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—COX2—peripheral nervous system neoplasm	1.2e-05	2.41e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—NRAS—peripheral nervous system neoplasm	1.19e-05	2.39e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.19e-05	2.39e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—ERBB2—peripheral nervous system neoplasm	1.18e-05	2.38e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—HRAS—peripheral nervous system neoplasm	1.18e-05	2.37e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.14e-05	2.28e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.13e-05	2.27e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.13e-05	2.27e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—AKT1—peripheral nervous system neoplasm	1.13e-05	2.26e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.11e-05	2.23e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—MYC—peripheral nervous system neoplasm	1.11e-05	2.23e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.09e-05	2.2e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—AKT1—peripheral nervous system neoplasm	1.08e-05	2.18e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	1.07e-05	2.15e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.06e-05	2.13e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.05e-05	2.11e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.05e-05	2.11e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—AKT1—peripheral nervous system neoplasm	1.04e-05	2.09e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.03e-05	2.08e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.03e-05	2.07e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.02e-05	2.06e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1e-05	2.02e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—TP53—peripheral nervous system neoplasm	1e-05	2.02e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CASP3—peripheral nervous system neoplasm	9.92e-06	2e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—NRAS—peripheral nervous system neoplasm	9.75e-06	1.96e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—HRAS—peripheral nervous system neoplasm	9.69e-06	1.95e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CASP3—peripheral nervous system neoplasm	9.62e-06	1.94e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—HRAS—peripheral nervous system neoplasm	9.58e-06	1.93e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—HRAS—peripheral nervous system neoplasm	9.41e-06	1.89e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—HRAS—peripheral nervous system neoplasm	9.13e-06	1.84e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	9.09e-06	1.83e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—NRAS—peripheral nervous system neoplasm	9e-06	1.81e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—HRAS—peripheral nervous system neoplasm	8.69e-06	1.75e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—TP53—peripheral nervous system neoplasm	8.62e-06	1.73e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	8.57e-06	1.72e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—AKT1—peripheral nervous system neoplasm	8.56e-06	1.72e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—TP53—peripheral nervous system neoplasm	8.48e-06	1.71e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—AKT1—peripheral nervous system neoplasm	8.46e-06	1.7e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—MYC—peripheral nervous system neoplasm	8.38e-06	1.69e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—NRAS—peripheral nervous system neoplasm	8.32e-06	1.67e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—AKT1—peripheral nervous system neoplasm	8.31e-06	1.67e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	8.28e-06	1.67e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	8.24e-06	1.66e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	8.11e-06	1.63e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—NRAS—peripheral nervous system neoplasm	8.07e-06	1.62e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—AKT1—peripheral nervous system neoplasm	8.06e-06	1.62e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MYC—peripheral nervous system neoplasm	7.98e-06	1.61e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ENO2—peripheral nervous system neoplasm	7.86e-06	1.58e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	7.81e-06	1.57e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MYC—peripheral nervous system neoplasm	7.75e-06	1.56e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—AKT1—peripheral nervous system neoplasm	7.67e-06	1.54e-05	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	7.59e-06	1.53e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CASP3—peripheral nervous system neoplasm	7.52e-06	1.51e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MYC—peripheral nervous system neoplasm	7.51e-06	1.51e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	7.28e-06	1.46e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	7.16e-06	1.44e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—HRAS—peripheral nervous system neoplasm	7.13e-06	1.43e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	6.89e-06	1.39e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—BCHE—peripheral nervous system neoplasm	6.64e-06	1.34e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—HRAS—peripheral nervous system neoplasm	6.58e-06	1.32e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TP53—peripheral nervous system neoplasm	6.55e-06	1.32e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—TP53—peripheral nervous system neoplasm	6.36e-06	1.28e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—SLC2A1—peripheral nervous system neoplasm	6.34e-06	1.27e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NRAS—peripheral nervous system neoplasm	6.3e-06	1.27e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—AKT1—peripheral nervous system neoplasm	6.3e-06	1.27e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	6.27e-06	1.26e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—TH—peripheral nervous system neoplasm	6.25e-06	1.26e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TP53—peripheral nervous system neoplasm	6.17e-06	1.24e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—HRAS—peripheral nervous system neoplasm	6.08e-06	1.22e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—HRAS—peripheral nervous system neoplasm	5.9e-06	1.19e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MYC—peripheral nervous system neoplasm	5.87e-06	1.18e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—AKT1—peripheral nervous system neoplasm	5.81e-06	1.17e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	5.53e-06	1.11e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—AKT1—peripheral nervous system neoplasm	5.37e-06	1.08e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—AKT1—peripheral nervous system neoplasm	5.21e-06	1.05e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GNAS—peripheral nervous system neoplasm	5.1e-06	1.03e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ABCB1—peripheral nervous system neoplasm	5e-06	1.01e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TP53—peripheral nervous system neoplasm	4.82e-06	9.7e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—HRAS—peripheral nervous system neoplasm	4.61e-06	9.28e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—AKT1—peripheral nervous system neoplasm	4.07e-06	8.19e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—AKT1—peripheral nervous system neoplasm	1.38e-06	2.77e-06	CbGpPWpGaD
